Germline DNA damage response gene mutations as predictive biomarkers of immune checkpoint inhibitor efficacy.

The adjusted odds ratio for the concurrent TKI group did not reach statistical significance, but there was an impressive difference in ORR for the small number of patients included (DDR- 5% vs DDR+ 50%, adjusted ORR 18.95 (95% CI, 0.79-455.65).

also in 111,027 other papers